Duchesnay Inc. Receives Approval of Supplemental New Drug Application (sNDA) to Add Moderate to Severe Vaginal Dryness, a Symptom of Vulvar and Vaginal Atrophy (VVA) Due to Menopause, to the Indication of Ospemifene
Duchesnay USA Applauds Expanded Coverage for Treatments for Dyspareunia due to Menopause under Medicare Part D
Duchesnay Inc. Announces Submission of Supplemental New Drug Application (sNDA) for Ospemifene to U.S. FDA
Duchesnay USA Continues the Morning Sickness Conversation with Actress, Mom and Singer Jana Kramer and Beverly Hills Ob/Gyn Dr. Jay Goldberg
Duchesnay Inc. to Present a Poster on Adherence, Persistence and Healthcare Costs Associated with Ospemifene at 2018 Annual Meeting of the North American Menopause Society (NAMS)
Duchesnay Inc. to Present a Poster on Ospemifene at the 2018 Annual Meeting of the North American Menopause Society (NAMS)
